FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2953849562> ?p ?o ?g. }

• W2953849562 endingPage "222" @default.
• W2953849562 startingPage "222" @default.
• W2953849562 abstract "Abstract Whilst antibody drug conjugates (ADCs) have been successfully used to target highly potent cytotoxic agents to tumours, there is a continued emphasis on developing technologies for improving the therapeutic effectiveness of this class of agents. The vast majority of ADCs that have entered the clinic have been based on large intact immunoglobulins, however, there is significant interest in exploiting small protein domains as the payload delivery vehicle. These offer a number of potential benefits over full length antibodies including increased tumour penetration, amenability to protein engineering and site-specific conjugation, and improved tolerability. To this end, we have developed a therapeutics platform based on shark Variable New Antigen Receptor (VNAR) proteins. Shark VNAR domains are the smallest naturally occurring antigen binding domain (~11 kDa), with a binding mechanism distinct from traditional antibodies. Here we report the application of this platform to the development of homogenous VNAR-drug conjugates targeting the onco-embryonic receptor tyrosine kinase ROR1. ROR1 expression has been observed across a broad range of solid tumours and haematological malignancies, and is reported to correlate with poor clinical outcome for a number of cancer indications, but is largely absent from normal adult tissue. As such, the expression pattern of ROR1, coupled with its functional role in tumourogenesis and disease progression, make it an attractive PDC target. Using a combination of direct immunisation and synthetic VNAR library screening, we have generated high affinity binders to the extracellular domain of ROR1 which show species cross-reactivity, do not bind the closely related family member ROR2, and can target distinct non-overlapping regions of the protein. By exploiting the ability of VNAR domains to be flexibly reformatted, the lead sequences have been configured as a series of bivalent Fc fusions, VNAR multimers and novel bi-paratopic binders, and constructs identified that show further enhanced binding to ROR1 and which can induce internalisation and lysosomal trafficking in ROR1 expressing cancer cell-lines. Subsequent attachment of highly potent DNA-damaging cytotoxic payloads yielded homogenous VNAR-drug conjugates which demonstrated extremely potent (sub-nanomolar) in vitro cytotoxicity against selected cancer cell-lines in a receptor mediated fashion. Studies to assess the in vivo efficacy of these conjugates are in progress. These ROR1 VNAR constructs have also been successfully fused to sdAbs and scFv directed to other cell-surface protein targets, demonstrating the power of the platform and opening the way for novel bi-specific approaches for targeting both solid and haematological tumours. Citation Format: Graham Cotton, Jennifer Thom, Paul Trumper, Stacey Bell, Andrei Kamenski, Mark Wappett, Caroline Barelle, Marina Kovaleva, John Steven, Andy Porter, Estelle McLean, Chiara Saladino, Aidan McCann, Aaron Cranston, Tim Harrison. Novel protein drug conjugates targeting ROR1 through the development and exploitation of a drug discovery platform based on small, engineered VNAR domains [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 222." @default.
• W2953849562 created "2019-07-12" @default.
• W2953849562 creator A5003432641 @default.
• W2953849562 creator A5008727334 @default.
• W2953849562 creator A5011032790 @default.
• W2953849562 creator A5012106881 @default.
• W2953849562 creator A5012660136 @default.
• W2953849562 creator A5016741225 @default.
• W2953849562 creator A5023361742 @default.
• W2953849562 creator A5032281279 @default.
• W2953849562 creator A5044617593 @default.
• W2953849562 creator A5046060433 @default.
• W2953849562 creator A5068944725 @default.
• W2953849562 creator A5076845937 @default.
• W2953849562 creator A5076903377 @default.
• W2953849562 creator A5079532494 @default.
• W2953849562 creator A5091121185 @default.
• W2953849562 date "2019-07-01" @default.
• W2953849562 modified "2023-10-18" @default.
• W2953849562 title "Abstract 222: Novel protein drug conjugates targeting ROR1 through the development and exploitation of a drug discovery platform based on small, engineered VNAR domains" @default.
• W2953849562 doi "https://doi.org/10.1158/1538-7445.am2019-222" @default.
• W2953849562 hasPublicationYear "2019" @default.
• W2953849562 type Work @default.
• W2953849562 sameAs 2953849562 @default.
• W2953849562 citedByCount "2" @default.
• W2953849562 countsByYear W29538495622020 @default.
• W2953849562 countsByYear W29538495622021 @default.
• W2953849562 crossrefType "journal-article" @default.
• W2953849562 hasAuthorship W2953849562A5003432641 @default.
• W2953849562 hasAuthorship W2953849562A5008727334 @default.
• W2953849562 hasAuthorship W2953849562A5011032790 @default.
• W2953849562 hasAuthorship W2953849562A5012106881 @default.
• W2953849562 hasAuthorship W2953849562A5012660136 @default.
• W2953849562 hasAuthorship W2953849562A5016741225 @default.
• W2953849562 hasAuthorship W2953849562A5023361742 @default.
• W2953849562 hasAuthorship W2953849562A5032281279 @default.
• W2953849562 hasAuthorship W2953849562A5044617593 @default.
• W2953849562 hasAuthorship W2953849562A5046060433 @default.
• W2953849562 hasAuthorship W2953849562A5068944725 @default.
• W2953849562 hasAuthorship W2953849562A5076845937 @default.
• W2953849562 hasAuthorship W2953849562A5076903377 @default.
• W2953849562 hasAuthorship W2953849562A5079532494 @default.
• W2953849562 hasAuthorship W2953849562A5091121185 @default.
• W2953849562 hasConcept C101544691 @default.
• W2953849562 hasConcept C147483822 @default.
• W2953849562 hasConcept C159654299 @default.
• W2953849562 hasConcept C170493617 @default.
• W2953849562 hasConcept C203014093 @default.
• W2953849562 hasConcept C2777325958 @default.
• W2953849562 hasConcept C2780035454 @default.
• W2953849562 hasConcept C502942594 @default.
• W2953849562 hasConcept C542903549 @default.
• W2953849562 hasConcept C55493867 @default.
• W2953849562 hasConcept C60644358 @default.
• W2953849562 hasConcept C64903051 @default.
• W2953849562 hasConcept C70721500 @default.
• W2953849562 hasConcept C71924100 @default.
• W2953849562 hasConcept C74187038 @default.
• W2953849562 hasConcept C86803240 @default.
• W2953849562 hasConcept C98274493 @default.
• W2953849562 hasConceptScore W2953849562C101544691 @default.
• W2953849562 hasConceptScore W2953849562C147483822 @default.
• W2953849562 hasConceptScore W2953849562C159654299 @default.
• W2953849562 hasConceptScore W2953849562C170493617 @default.
• W2953849562 hasConceptScore W2953849562C203014093 @default.
• W2953849562 hasConceptScore W2953849562C2777325958 @default.
• W2953849562 hasConceptScore W2953849562C2780035454 @default.
• W2953849562 hasConceptScore W2953849562C502942594 @default.
• W2953849562 hasConceptScore W2953849562C542903549 @default.
• W2953849562 hasConceptScore W2953849562C55493867 @default.
• W2953849562 hasConceptScore W2953849562C60644358 @default.
• W2953849562 hasConceptScore W2953849562C64903051 @default.
• W2953849562 hasConceptScore W2953849562C70721500 @default.
• W2953849562 hasConceptScore W2953849562C71924100 @default.
• W2953849562 hasConceptScore W2953849562C74187038 @default.
• W2953849562 hasConceptScore W2953849562C86803240 @default.
• W2953849562 hasConceptScore W2953849562C98274493 @default.
• W2953849562 hasIssue "13_Supplement" @default.
• W2953849562 hasLocation W29538495621 @default.
• W2953849562 hasOpenAccess W2953849562 @default.
• W2953849562 hasPrimaryLocation W29538495621 @default.
• W2953849562 hasRelatedWork W1990688647 @default.
• W2953849562 hasRelatedWork W2093033902 @default.
• W2953849562 hasRelatedWork W2133768972 @default.
• W2953849562 hasRelatedWork W2143400953 @default.
• W2953849562 hasRelatedWork W2152784570 @default.
• W2953849562 hasRelatedWork W2461520869 @default.
• W2953849562 hasRelatedWork W2569242362 @default.
• W2953849562 hasRelatedWork W2772481372 @default.
• W2953849562 hasRelatedWork W2953381357 @default.
• W2953849562 hasRelatedWork W2991546386 @default.
• W2953849562 hasVolume "79" @default.
• W2953849562 isParatext "false" @default.
• W2953849562 isRetracted "false" @default.
• W2953849562 magId "2953849562" @default.
• W2953849562 workType "article" @default.